Related Experiment Video
Updated: Aug 14, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Nateglinide: a new rapid-acting insulinotropic agent
1Department of Medicine, Birmingham Heartlands Hospital & University of Birmingham, UK.
Expert Opinion on Pharmacotherapy
|October 5, 2001
Summary
Tight control of post-prandial hyperglycemia, particularly with nateglinide, may reduce cardiovascular mortality in Type 2 diabetes. This approach targets glucose spikes after meals, offering a new therapeutic option.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetology
Background:
- Tight glycemic control in Type 2 diabetes (T2D) reduces microvascular but not macrovascular complications.
- Post-prandial hyperglycemia is more strongly linked to cardiovascular complications than fasting hyperglycemia.
- Previous studies may have underestimated the impact of controlling post-meal glucose levels on cardiovascular mortality.
Purpose of the Study:
- To investigate the potential benefits of targeting post-prandial hyperglycemia for reducing cardiovascular mortality in T2D.
- To evaluate nateglinide's role in managing post-prandial glucose excursions.
- To explore combination therapy with metformin for comprehensive glycemic control.
Main Methods:
- Nateglinide, a D-phenylalanine derivative, inhibits ATP-sensitive K+ channels in pancreatic beta-cells.
- Nateglinide restores first-phase insulin response, reducing post-prandial glucose spikes.
- Combination studies assessed nateglinide's efficacy with metformin in T2D patients.
Main Results:
- Nateglinide effectively reduces post-prandial glucose excursions.
- Metformin primarily lowers basal plasma glucose levels.
- Combination therapy with nateglinide and metformin demonstrates effectiveness in overall hyperglycemia control.
Conclusions:
- Nateglinide offers a novel therapeutic strategy for T2D by specifically addressing post-prandial hyperglycemia.
- Targeting post-meal glucose fluctuations is crucial for potentially mitigating cardiovascular risks in T2D.
- Combination therapy may provide synergistic benefits for glycemic management in T2D.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...